Viatris Inc
0.22 (2.33%)


Draw Mode:

Volume 4,462,583
Bid Price 9.66
Ask Price 9.67
News -
Day High 9.80


52 Week Range


Day Low 9.57
Company Name Stock Ticker Symbol Market Type
Viatris Inc VTRS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.22 2.33% 9.66 12:33:08
Open Price Low Price High Price Close Price Prev Close
9.57 9.57 9.80 9.44
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
19,163 4,462,583 $ 9.69 $ 43,232,947 - 8.42 - 12.3993
Last Trade Time Type Quantity Stock Price Currency
12:33:08 100 $ 9.66 USD

Viatris Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 11.56B 1.20B 1.06B $ 16.26B $ 2.11B 1.71 5.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 0.48 5.09% 03/08/23 - 0.30%

more financials information »

Viatris News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No VTRS Message Board. Create One! See More Posts on VTRS Message Board See More Message Board Posts

Historical VTRS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.0010.029.239.5211,351,400-0.34-3.4%
1 Month11.6111.809.2310.5610,344,484-1.95-16.8%
3 Months11.0312.39939.2311.299,378,417-1.37-12.42%
6 Months9.1912.39938.4210.719,475,2640.475.11%
1 Year10.5812.39938.4210.5910,531,293-0.92-8.7%
3 Years16.4618.868.4212.8410,481,775-6.80-41.31%
5 Years16.4618.868.4212.8410,481,775-6.80-41.31%

Viatris Description

Viatris Inc is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).